Livzon Pharmaceutical Group Inc. (hereinafter referred to as "Livzon Group")

Lizhu Group, located in Zhuhai Special Economic Zone of Guangdong Province, adjacent to Macao Special Administrative Region, is listed on Shenzhen Stock Exchange (stock code: A-share - 000513, B-share - 200513). Founded in January 1985, it was formerly A state-owned enterprise and completed the shareholding reform in 1993, becoming the first A and B-share listed company in the pharmaceutical industry in China. The company produces "Lizhu Deluo" stomach medicine best-selling more than 20 years, become a household name brand. In April 2002, Shenzhen Healthyuan Pharmaceutical Group Co., LTD. (formerly Known as Shenzhen Wife Pharmaceutical Co., LTD., listed in Shanghai Stock Exchange, code: 600380) acquired and controlled Lizhu Group and became the largest shareholder of Lizhu Group. Since then, Lizhu Group has started a new development course.

Since 2003, Lizhu Group has been recognized by the Ministry of Science and Technology as a "National Torch Program Key High-tech Enterprise". It has national enterprise technology center, National Engineering technology Research Center of Chinese Medicine modernization and other RESEARCH and development institutions. In 2009, the group ranked 37th among the top 100 pharmaceutical companies in China, and was also awarded "Top 50 Listed Companies with Most Investment Value in Guangdong in 2009", "Top 100 Enterprises in Guangdong In 2009", etc.

Lizhu Group has more than 20 wholly owned or co-owned enterprises, more than 5,000 employees, more than 400 pharmaceutical approval documents, 53 production lines have passed GMP certification, the products cover chemical drugs, Chinese patent drugs, biochemical drugs, bioengineering drugs, microecological preparations, active pharmaceutical ingredients (pharmaceutical intermediates), diagnostic reagents, etc. In 2010, Lizhu Group realized sales revenue of 2.727 billion yuan, net profit of 418 million yuan, total assets of 3.662 billion yuan, net assets of 2.639 billion yuan.

Lizhu Group Ningxia Fuxing Pharmaceutical Co., LTD. (hereinafter referred to as "Ningxia Fuxing")

Ningxia fusing by Livzon Pharmaceutical Group Inc., and its subsidiaries - fuzhou fusing method Group Pharmaceutical co., LTD., a joint investment, ningxia fusing biological medicine production and construction project in July 2011 in ningxia hui autonomous region economic and information commission agreed to project construction, construction began in February 2012, after three years time, in May 2015 to complete the project completion inspection and acceptance, and formally put into production.

Lizhu Group Ningxia New Beijiang Pharmaceutical Co., LTD. (hereinafter referred to as "Ningxia New Beijiang").

Ningxia Xinbeijiang Was jointly invested by Livzon Pharmaceutical Group Inc. and its subsidiary, Lizhu Xinbeijiang Pharmaceutical Co., LTD.